Using MRI to evaluate lung tumors and thoracic cancers
Metabolic Biomarkers in Thoracic Cancers
This study is testing a new MRI method to see if it can better track lung tumors and other chest cancers using a special sugar solution during surgery, aiming to make monitoring these growths safer and easier.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Texas Southwestern Medical Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT02095808 on ClinicalTrials.gov |
What this trial studies
This research focuses on developing a method to utilize magnetic resonance imaging (MRI) for assessing lung tumors and other thoracic malignancies. The study aims to investigate the metabolic pathways of pulmonary nodules as they utilize sugar for growth, employing a modified sugar solution (13C-glucose) during surgical tumor removal. By analyzing imaging biomarkers, the goal is to create more accurate, less invasive imaging algorithms for monitoring these nodules without the use of ionizing radiation. The study builds on previous findings that suggest promising imaging techniques can enhance the characterization of malignancies.
Who should consider this trial
Good fit: Ideal candidates include patients over 18 years old with known or probable malignant lesions that require surgical intervention.
Not a fit: Patients who are not surgical candidates or have poorly controlled diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved diagnostic accuracy and monitoring of lung cancer, potentially reducing the need for invasive procedures.
How similar studies have performed: Other studies have shown promise in using imaging biomarkers for cancer characterization, suggesting this approach may yield beneficial results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients must have known or probable malignant lesions requiring surgical biopsy or excision. 2. Subjects of all races and ethnic origins over 18 years of age. Exclusion Criteria: 1. Not a surgical candidate. 2. Poorly controlled diabetes.
Where this trial is running
Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Kemp H Kernstine, MD — University of Texas Southwestern Medical Center
- Study coordinator: Ebele Mbanugo, Ed.D, CCRP
- Email: ebele.mbanugo@utsouthwestern.edu
- Phone: 214-648-7097
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.